Alzinova has reported positive top-line results from its phase 1b clinical trial of the vaccine candidate ALZ-101 in Alzheimer’s disease.

“The positive top-line results further strengthen our confidence in that ALZ-101 can become a unique therapeutic vaccine and thus help patients suffering from Alzheimer’s disease and their families to a better life. Alzinova has the potential to revolutionise the treatment of Alzheimer’s, and we look forward to the final analysis, where we will see outcomes on several different endpoints. This result also strengthens our position in discussions with potential partners,” says Alzinova’s CEO Kristina Torfgård.

This result also strengthens our position in discussions with potential partners.”

A first analysis of the study data shows that ALZ-101 has continued good tolerability, an acceptable safety profile and a high immune responder rate. Furthermore, the results show that patients treated with ALZ-101 responded with antibody levels that increased with the number of doses given.

A full analysis of the study data is expected to be completed in the first quarter of 2024.”

A full analysis of the study data is expected to be completed in the first quarter of 2024. The positive results support continued clinical development of ALZ-101, and preparations for a planned phase 2 study are ongoing, the company states.

Photo of Kristina Torfgård